Global health risk framework [electronic resource] : research and development of medical products : workshop summary
| 000 | 00000cam u2200205 a 4500 | |
| 001 | 000045984966 | |
| 005 | 20190603090837 | |
| 006 | m d | |
| 007 | cr | |
| 008 | 190529s2016 dcu ob 100 0 eng d | |
| 020 | ▼a 9780309380997 | |
| 020 | ▼a 0309380995 | |
| 020 | ▼a 9780309381000 | |
| 020 | ▼a 0309381002 | |
| 035 | ▼a 1159281 ▼b (N$T) | |
| 035 | ▼a (OCoLC)949829885 | |
| 040 | ▼a NLM ▼b eng ▼e rda ▼e pn ▼c NLM ▼d CUS ▼d N$T ▼d OCLCF ▼d DOS ▼d OCLCO ▼d OCLCA ▼d YDX ▼d SNK ▼d DKU ▼d INTCL ▼d IGB ▼d D6H ▼d VTS ▼d EZ9 ▼d AGLDB ▼d OCLCQ ▼d 211009 | |
| 050 | 0 0 | ▼a RA651 |
| 082 | 0 4 | ▼a 614.4 ▼2 23 |
| 084 | ▼a 614.4 ▼2 DDCK | |
| 090 | ▼a 614.4 | |
| 245 | 0 0 | ▼a Global health risk framework ▼h [electronic resource] : ▼b research and development of medical products : workshop summary / ▼c Theresa Wizemann, Michelle A. Mancher, and Anne B. Claiborne, rapporteurs ; Board of Health Sciences Policy, Institute of Medicine, the National Academies of Sciences, Engineering, Medicine. |
| 260 | ▼a Washington, DC : ▼b The National Academies Press, ▼c c2016. | |
| 300 | ▼a 1 online resource (xvi, 124 p.). | |
| 500 | ▼a Title from e-Book title page. | |
| 504 | ▼a Includes bibliographical references. | |
| 505 | 0 | ▼a Introduction -- Models and incentives for engagement -- Discovery research -- Development -- Convergence of regulatory expections, review, and approval -- Manufacturing, stockpiling, and distribution -- Critical considerations for facilitating medical product research and development -- Crosscutting themes and closing remarks -- Appendix A: References -- Appendix B: Workshop statement of task -- Appendix C: Workshop agenda -- Appendix D: Workshop speaker biographies. |
| 520 | 3 | ▼a Since the 2014 Ebola outbreak many public- and private-sector leaders have seen a need for improved management of global public health emergencies. The effects of the Ebola epidemic go well beyond the three hardest-hit countries and beyond the health sector. Education, child protection, commerce, transportation, and human rights have all suffered. The consequences and lethality of Ebola have increased interest in coordinated global response to infectious threats, many of which could disrupt global health and commerce far more than the recent outbreak. In order to explore the potential for improving international management and response to outbreaks the National Academy of Medicine agreed to manage an international, independent, evidence-based, authoritative, multistakeholder expert commission. As part of this effort, the Institute of Medicine convened four workshops in summer of 2015 to inform the commission report. The presentations and discussions from the Workshop on Research and Development of Medical Products are summarized in this report. |
| 530 | ▼a Issued also as a book. | |
| 536 | ▼a This activity was supported by Sponsor Award No. 11849 from the Paul G. Allen Family Foundation, Grant No. 0150-0653 from the Ford Foundation, Investment ID OPP1130763 from The Bill & Melinda Gates Foundation, Dr. Ming Wai Lau, Grant No. 4829 from the Gordon and Betty Moore Foundation, Grant No. 2015 EBO 308 from The Rockefeller Foundation, Award No. GHN-G-00-07-00001-00 from the U.S. Agency for International Development, and the Wellcome Trust. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. | |
| 538 | ▼a Mode of access: World Wide Web. | |
| 650 | 0 | ▼a Diseases ▼x Risk factors. |
| 650 | 0 | ▼a World health. |
| 650 | 0 | ▼a Epidemiology. |
| 650 | 0 | ▼a Mortality. |
| 650 | 1 2 | ▼a Communicable Disease Control. |
| 650 | 2 2 | ▼a Vaccines. |
| 650 | 2 2 | ▼a Pandemics ▼x prevention & control. |
| 650 | 2 2 | ▼a Drug Discovery. |
| 650 | 2 2 | ▼a International Cooperation. |
| 650 | 2 2 | ▼a Global Health. |
| 700 | 1 | ▼a Wizemann, Theresa M. |
| 700 | 1 | ▼a Mancher, Michelle. |
| 700 | 1 | ▼a Claiborne, Anne B. |
| 710 | 2 | ▼a Institute of Medicine (U.S.). ▼b Board on Health Sciences Policy. |
| 710 | 2 | ▼a National Academies of Sciences, Engineering, and Medicine (U.S.). |
| 711 | 2 | ▼a Global Health Risk Framework: Research and Development of Medical Products (Workshop) ▼d (2015 : ▼c Hong Kong, China). |
| 856 | 4 0 | ▼3 EBSCOhost ▼u https://oca.korea.ac.kr/link.n2s?url=http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=1159281 |
| 945 | ▼a KLPA | |
| 991 | ▼a E-Book(소장) |
소장정보
| No. | 소장처 | 청구기호 | 등록번호 | 도서상태 | 반납예정일 | 예약 | 서비스 |
|---|---|---|---|---|---|---|---|
| No. 1 | 소장처 중앙도서관/e-Book 컬렉션/ | 청구기호 CR 614.4 | 등록번호 E14012737 | 도서상태 대출불가(열람가능) | 반납예정일 | 예약 | 서비스 |
컨텐츠정보
책소개
Since the 2014 Ebola outbreak many public- and private-sector leaders have seen a need for improved management of global public health emergencies. The effects of the Ebola epidemic go well beyond the three hardest-hit countries and beyond the health sector. Education, child protection, commerce, transportation, and human rights have all suffered. The consequences and lethality of Ebola have increased interest in coordinated global response to infectious threats, many of which could disrupt global health and commerce far more than the recent outbreak.
In order to explore the potential for improving international management and response to outbreaks the National Academy of Medicine agreed to manage an international, independent, evidence-based, authoritative, multistakeholder expert commission. As part of this effort, the Institute of Medicine convened four workshops in summer of 2015 to inform the commission report. The presentations and discussions from the Workshop on Research and Development of Medical Products are summarized in this report.
정보제공 :
목차
Acronyms and Abbreviations p. xv
1 Introduction p. 1
The Global Health Risk Framework Initiative p. 2
The Workshop on Research and Development of Medical Products p. 2
WHO Perspective on the Global Health Risk Framework p. 5
2 Models and Incentives for Engagement p. 11
Public-Private Partnerships as the Essential Operating Model p. 13
Creating a Blend of Incentives for Engagement of Partners p. 18
Elements of Success p. 21
Challenges p. 22
3 Discovery Research p. 25
Advancing the Science of Discovery p. 27
Intellectual Property and Sharing of Data and Reagents p. 32
Liability p. 38
4 Development p. 39
Ethical Principles and Methodological Framework for Clinical Trial Designs p. 41
Methodological Design Considerations p. 41
Ethical Review p. 47
Regulatory Perspective p. 47
Practical Considerations and Community Engagement p. 49
5 Convergence of Regulatory Expectations, Review, and Approval p. 55
Coordination, Harmonization, and Convergence p. 56
6 Manufacturing, Stockpiling, and Distribution p. 63
Policy Perspective p. 65
Manufacturing Capacity p. 68
Stockpiling Logistics p. 70
Supply Chain and Distribution p. 71
Forecasting Demand p. 73
7 Critical Considerations for Facilitating Medical Product Research and Development p. 75
Defining the Priorities for Research and Development p. 75
Incentives p. 78
Discovery p. 79
Development p. 79
Regulations p. 80
Manufacturing p. 80
Distribution p. 81
8 Crosscutting Themes and Closing Remarks p. 83
Closing Remarks p. 84
Appendixes
A References p. 87
B Workshop Statement of Task p. 89
C Workshop Agenda p. 91
D Workshop Speaker Biographies p. 101
